CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Original Research2020 Jul 18.

JOURNAL:ESC Heart Fail. Article Link

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study

JA Borovac, D Glavas, ZS Grabovac et al. Keywords: acute decompensated heart failure; catestatin; HF; hospital mortality; risk stratification; soluble suppression of tumourigenicity

Full Text PDF